| 规格: | 98% |
| 分子量: | 336.39 |
| 包装 | 价格(元) |
| 250mg | 电议 |
| 500mg | 电议 |
Background:
Vafidemstat (ORY-2001) is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor.
Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease[2].
[1]. ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer's and Parkinson's diseases [2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018.
m.cnreagent.com